CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 194 enrolled
Drug / intervention
Dupilumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02210780
NCT02210780Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab

Regeneron Pharmaceuticals·interventional·Posted Aug 7, 2014·Updated May 7, 2020

In Brief

A Phase 2 clinical trial evaluating Dupilumab and Placebo for Atopic Dermatitis. Completed, enrolled 194 participants across 42 sites.

Detailed Summary

This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsSanofi

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 7, 2014
Enrollment StartAug 5, 2014
Primary CompletionSep 15, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.9 years ago

Interventions

Dupilumabdrug

Administered via subcutaneous injection.

Placebodrug

An inactive substance containing no medicine administered via subcutaneous injection.